Surprise Discovery About Sugar in The Brain Could Help Fight Alzheimer's
Alzheimer's is a tauopathy; a condition characterized by harmful build-ups of tau proteins inside neurons. It's not clear, however, if these build-ups are a cause or a consequence of the disease. A new study now adds important detail by revealing significant interactions between tau and glucose in its stored form of glycogen.
Led by a team from the Buck Institute for Research on Aging in the US, the research sheds new light on the functions of glycogen in the brain. Before now, it's only been regarded as an energy backup for the liver and the muscles.
"This new study challenges that view, and it does so with striking implications," says molecular biologist Pankaj Kapahi, from the Buck Institute. "Stored glycogen doesn't just sit there in the brain, it is involved in pathology."
Related:
Building on links previously found between glycogen and neurodegeneration, the researchers spotted evidence of excessive glycogen levels both in tauopathy models created in fruit flies (Drosophila melanogaster) and in the brain cells of people with Alzheimer's.
Further analysis revealed a key mechanism at play: tau proteins interrupt the normal breakdown and use of glycogen in the brain, adding to the dangerous build-up of both tau and glycogen, as well as lowering protective neuron defense barriers.
Crucial to this interaction is the activity of glycogen phosphorylase or GlyP, the main enzyme tasked with turning glycogen into a fuel the body can use. When the researchers boosted GlyP production in fruit flies, glycogen stores were utilized once more, helping to fight back against cell damage.
"By increasing GlyP activity, the brain cells could better detoxify harmful reactive oxygen species, thereby reducing damage and even extending the lifespan of tauopathy model flies," says Buck Institute biologist Sudipta Bar.
The team wondered if a restricted diet – already associated with better brain health – would help. When fruit flies affected by tauopathy were put on a low-protein diet, they lived longer and showed reduced brain damage, suggesting that the metabolic shift prompted by dieting can help boost GlyP.
It's a notable set of findings, not least because it suggests a way that glycogen and tau aggregation could be tackled in the brain. The researchers also developed a drug based around the 8-Br-cAMP molecule to mimic the effects of dietary restriction, which had similar effects on flies in experiments.
The work might even tie into research involving GLP-1 receptor agonists such as Ozempic, designed to manage diabetes and reduce weight, but also now showing promise for protecting against dementia. That might be because these drugs interact with one of glycogen's pathways, the researchers suggest.
"By discovering how neurons manage sugar, we may have unearthed a novel therapeutic strategy: one that targets the cell's inner chemistry to fight age-related decline," says Kapahi.
"As we continue to age as a society, findings like these offer hope that better understanding – and perhaps rebalancing – our brain's hidden sugar code could unlock powerful tools for combating dementia."
The research has been published in Nature Metabolism.
Air Pollution 'Strongly Associated' With DNA Mutations Tied to Lung Cancer
FDA Issues Warning Over Dangerous 'Gas Station Heroin' Substance
Mysterious Leprosy Pathogen Has Lurked in The Americas For 4,000 Years
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
an hour ago
- Business Wire
Aptar's Dual-Active Material Science Technology Simultaneously Controls Moisture and Oxygen for Pharmaceutical Drugs and Medical Devices
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that it has developed a dual-active material science technology engineered to simultaneously control moisture and oxygen. This technology is designed to provide a singular solution to address these degradation drivers for pharmaceutical drugs, including oral solid dose glucagon-like peptide-1 (GLP-1), medical devices and more. This new solution marks a significant material science breakthrough in the pharmaceutical industry, extending Aptar CSP Technologies' 3-Phase Activ-Polymer™ technology into new use cases where a combination of humidity and oxidation can compromise the efficacy, safety, and shelf life of sensitive oral solid dose drugs, medical devices, implantable mesh devices, microarray patches and transdermal delivery systems. 'This launch reflects years of development, engineering excellence, and a deep understanding of our customers' most pressing stability challenges,' said Badre Hammond, Vice President Commercial Operations and General Manager, Aptar CSP Technologies. 'There has never been a singular, standalone active material aimed at protecting against both oxidation and moisture-related degradation at this level of precision across multiple platforms. We're proud to offer a solution that is not only scientifically differentiated but can also be commercially validated.' Aptar's new dual-active technology can be customized for a range of product formats and development stages, from early R&D to commercial launch. Aptar's technology can help support regulatory compliance and product protection across a variety of formats, aimed at helping companies meet strict International Council for Harmonization (ICH) stability requirements while maintaining performance and integrity of sensitive drug or device components. In addition to protection technology for oral solid dose GLP-1, Aptar also offers a range of high-quality elastomeric components for GLP-1 drug products, including plungers and rigid needle shields. Pharmaceutical companies have validated Aptar's elastomeric components and are partnering with Aptar to develop injectable solutions for GLP-1. By combining digital and Aptar's patient services, Aptar offers fully integrated solutions, which helps drug manufacturers create differentiated drug delivery systems and enhance patient experiences for GLP-1 and other applications. About Aptar Aptar is a global leader in drug and consumer product dosing, dispensing and protection technologies. Aptar serves a number of attractive end markets including pharmaceutical, beauty, food, beverage, personal care and home care. Aptar CSP Technologies leverages its active material science expertise to transform ideas into market opportunities, accelerate and de-risk the product development process, and provide complete solutions that improve consumers' and patients' lives. The company offers a complete set of services from concept ideation, to design and engineering, to product development, global production, quality control, and regulatory support that results in expedited speed-to-market. Aptar is headquartered in Crystal Lake, Illinois and has over 13,000 dedicated employees in 20 countries. For more information, visit and This press release contains forward-looking statements, including the potential outcomes of the 3-Phase Activ-Polymer™ technology. Forward-looking statements generally can be identified by the fact that they do not relate strictly to historical or current facts and by use of words such as 'expects,' 'anticipates,' 'believes,' 'estimates,' 'future,' 'potential,' 'continues' and other similar expressions or future or conditional verbs such as 'will,' 'should,' 'would' and 'could' are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results or other events may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: the successful integration of acquisitions; the regulatory environment; and competition, including technological advances. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' in our Form 10-K and Forms 10-Q. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as otherwise required by law.

Miami Herald
2 hours ago
- Miami Herald
Formerly bankrupt weight-loss company makes a comeback
When it comes to things that most concern Americans about their health, weight loss is often at the top of the list. While America doesn't have the top obesity rate in the world, it does rank high on the list. More than 45% of Americans are obese. But the issue is bigger than just in the country - the worldwide rate of adult obesity has more than doubled since 1990, per the World Health Organization. Don't miss the move: Subscribe to TheStreet's free daily newsletter Attempts to solve this problem have spawned a thriving diet industry, always promoting the next pill, diet plan, or weight-loss gimmick to those desperate to attain better health. These approaches have all propelled the U.S. weight-loss market to grow over the decades, but the birth of GLP-1 drugs such as Ozempic sent it to new heights in 2023, with a market value of $90 billion. Related: One of Oprah's favorite things prepares for Chapter 11 bankruptcy It's a profitable market, but also an overcrowded one, and trying to get people's attention and stay on the cutting edge of what appeals to consumers presents a daunting challenge that businesses must continually navigate. Now, after one of the best-known names in the industry seemed to be on the edge of extinction, it's making a turnaround that few could have predicted - and with a new focus on a long-ignored women's issue. After declaring Chapter 11 bankruptcy in May of 2025, once-giant WeightWatchers (rebranded to WW beginning in 2018) admitted its $1.5 billion in debt was too big of a burden to continue to bear. The bankruptcy process would eliminate that debt, the company said, and it expected to reemerge as a publicly traded company. "The decisive actions we're taking today, with the overwhelming support of our lenders and noteholders, will give us the flexibility to accelerate innovation, reinvest in our members, and lead with authority in a rapidly evolving weight management landscape," said CEO Tara Comonte in a release at the time. Related: WeightWatchers takes drastic step to exit bankruptcy WeightWatchers made its debut in the '60s, at a time when diet and portion control were a focus, and enjoyed many decades of success. The company also got a significant boost when Oprah partnered with it in 2015. WeightWatchers has now emerged from that bankruptcy with a new focus: helping middle-aged women struggling with all stages of menopause, from peri to post. The new program will offer access to prescription treatments such as hormone replacement therapy and also help women connect with resources for behavioral and nutritional support, WeightWatchers said. The company also named Dr. Kim Boyd as its new chief medical officer. Boyd has worked in leadership at One Medical, Calibrate, Caire, Galileo, and Nurx in the past and has co-founded or scaled multiple consumer health companies. Menopause care has been a hot topic as of late, with high-profile actresses such as Naomi Watts founding new companies to support women going through it. After Watts experienced early menopause at 36, she founded Stripes Beauty, a brand that sells products aimed at women in all stages of the life change. WW's new angle could provide the first large-scale platform for menopausal women, which could take advantage of a once-taboo topic that's slowly gained more attention in recent years. Related: Red-hot weight-loss drug stock tanks after surprise pharma giant decision The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
Yahoo
2 hours ago
- Yahoo
Morphic Medical obtains CE mark for obesity treatment
Morphic Medical has obtained an EU CE mark for RESET, a device designed to target the underlying cause of obesity and type 2 diabetes (T2D). The Boston-headquartered company's RESET is a novel duodenal-jejunal bypass liner (DJBL) that mimics the effect of gastric bypass surgery and is positioned as a less-invasive option for people with T2D and obesity who have not responded well to medications or require a 'bridge' ahead of bariatric surgery. Implanted endoscopically into the upper region of the small intestine and left in place for up to nine months, RESET creates a physical barrier between receptors in the intestinal wall and food. The approach has been demonstrated to improve weight reduction and metabolic conditions by enhancing natural hormones in the gut in a manner comparable to glucagon-like peptide-1 (GLP-1) agonists. A UK study conducted at the Sandwell and West Birmingham National Health Service (NHS) Trust demonstrated that RESET's use in individuals with diabetes and obesity resulted in an average weight reduction of 17.4kg at the three-year follow up after receiving the treatment, and a 1.9% reduction in blood glucose levels alongside improvements in blood pressure and cholesterol. Morphic Medical president and CEO, Joseph Virgilio commented: "This critical regulatory milestone is an important step toward delivering on our promise and accomplishing our mission to alleviate the symptoms of obesity and metabolic disorders such as T2D for patients fighting these global epidemics. 'We're excited to help patients who have failed to achieve their goals through a programme of diet, exercise, and medical management, and are looking for an alternative therapy.' RESET is currently only available for investigational use in the US. To support a regulatory filing with the US Food and Drug Administration (FDA), Morphic is currently enrolling patients in the STEP-1 RESET pivotal trial (NCT04101669). Planned for completion in 2026, STEP-1 is a multi-centre, randomised, sham-controlled trial that plans to enrol a total of 264 patients to evaluate the safety and effectiveness of RESET, as per the study's listing on "Morphic Medical obtains CE mark for obesity treatment" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.